GlassScriptPhysician profile
Susan E Broyles
NPI 1720352818
$3,355.38
in general payments reported to CMS, 2019-2025
30 companies · $574 in 2025
The $574 reported for 2025 was more than what 75% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,920 · 2022: $567 · 2023: $171 · 2024: $123 · 2025: $574.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $868.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $868.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $838.48 | 2021-2025 | |
| Janssen Biotech, INC. | $530.41 | 2021-2025 | Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $248.22 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $226.37 | 2022-2023 | Fasenra |
| Takeda Pharmaceuticals U.S.A., INC. | $223.19 | 2021-2024 | Hyqvia, Glassia |
| Celgene Corporation | $195.63 | 2021-2023 | |
| Alexion Pharmaceuticals, INC. | $146.59 | 2021-2025 | Ultomiris |
| Gilead Sciences, INC. | $126.14 | 2025 | Livdelzi |
| Intercept Pharmaceuticals, INC. | $122.74 | 2021 | |
| Glaxosmithkline, LLC. | $114.76 | 2022-2025 | Nucala |
| Braintree Laboratories, INC. | $64.37 | 2021 | |
| Nestle Healthcare Nutrition INC. | $49.75 | 2021 | |
| Ferring Pharmaceuticals INC. | $46.15 | 2021 | |
| Ipsen Biopharmaceuticals, INC | $45.50 | 2025 | Iqirvo |
| Intra-Sana Laboratories | $37.04 | 2021 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $34.04 | 2021 | |
| Genzyme Corporation | $31.87 | 2025 | |
| Argenx US, INC. | $30.48 | 2024 | Vyvgart Hytrulo |
| Horizon Therapeutics Plc | $29.32 | 2022 | |
| Amgen INC. | $29.16 | 2022 | |
| Redhill Biopharma INC. | $23.19 | 2021 | |
| Madrigal Pharmaceuticals | $22.42 | 2025 | Rezdiffra |
| Ardelyx, INC. | $21.90 | 2025 | Ibsrela |
| Regeneron Healthcare Solutions, INC. | $21.52 | 2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $21.15 | 2021 | |
| Evoke Pharma, INC. | $16.68 | 2021 | |
| Qol Medical, LLC | $16.35 | 2021 | |
| Pfizer INC. | $15.53 | 2021 | |
| Daiichi Sankyo INC. | $14.48 | 2021 | |
| Phathom Pharmaceuticals, INC. | $11.95 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Broyles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.